ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Carnitine supplements (Levocarnitine): Pediatric drug information

Carnitine supplements (Levocarnitine): Pediatric drug information
(For additional information see "Carnitine supplements (Levocarnitine): Drug information" and see "Carnitine supplements (Levocarnitine): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Carnitor;
  • Carnitor SF;
  • G-levOCARNitine S/F [OTC]
Brand Names: Canada
  • Carnitor;
  • ODAN Levocarnitine
Therapeutic Category
  • Nutritional Supplement
Dosing: Neonatal
Carnitine deficiency, treatment

Carnitine deficiency, treatment: Limited data available: Note: Variability in gene-specific mutations and clinical presentations exist; dosage should be individualized based upon patient response and serum carnitine concentrations with consultation with a metabolic specialist.

Primary deficiency: Preterm and term neonates: Oral: Initial: 50 to 100 mg/kg/day in divided doses; reported frequency varies from 2 to 4 times daily up to every 3 to 4 hours; titrate slowly as needed based on serum carnitine concentrations; reported range: 100 to 400 mg/kg/day in divided doses (Almannai 2019; BIMDG 2016a; BIMDG 2020; Longo 2006; Longo 2016; Magoulas 2012; Rasania 2021; Stanley 2020; manufacturer's labeling).

Secondary deficiency (other inborn errors of metabolism):

Preterm and term neonates:

Oral: Initial: 50 to 100 mg/kg/day in divided doses; reported frequency varies from 2 to 4 times daily up to every 3 to 4 hours; titrate slowly as needed based on patient response to usual reported dose: 100 to 200 mg/kg/day in divided doses; some conditions may require higher daily doses (eg, 300 mg/kg/day) (BIMDG 2016b; BIMDG 2020; Boy 2017; Burton 2021; Sutton 2012; Wojcik 2022; manufacturer's labeling).

IV: 50 to 100 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, administer a loading dose followed by an equivalent dose given over the next 24 hours as a continuous infusion or divided every 3 to 6 hours; some conditions may require higher daily doses (eg, 300 mg/kg/day) (BIMDG 2016b; Boy 2017; Sutton 2012; manufacturer's labeling).

Parenteral nutrition, supplement

Parenteral nutrition, supplement: Limited data available: Preterm and term neonates: Note: Neonates weighing <5 kg are generally carnitine deficient and require supplementation: IV: Initial: 2 to 5 mg/kg/day in parenteral nutrition solution; higher doses up to 10 to 20 mg/kg/day may be necessary in patients with elevated triglyceride levels or receiving parenteral nutrition longer than 7 days; free and total plasma carnitine concentrations should be monitored and doses adjusted accordingly (ASPEN [Corkins 2015]; ASPEN [Vanek 2012]).

Dosing: Pediatric
Carnitine deficiency, treatment

Carnitine deficiency, treatment:

Note: Variability in gene-specific mutations and clinical presentations exist; dosage should be individualized based upon patient response and serum carnitine concentrations with consultation with a metabolic specialist.

Primary deficiency: Infants, Children, and Adolescents: Oral: Initial: 50 to 100 mg/kg/day in divided doses; reported frequency varies from 2 to 4 times daily up to every 3 to 4 hours; may titrate slowly as needed based on serum carnitine concentrations; reported range: 100 to 400 mg/kg/day; maximum daily dose: 3,000 mg/day (Almannai 2019; BIMDG 2016a; BIMDG 2020; Longo 2006; Longo 2016; Magoulas 2012; Stanley 2020; manufacturer's labeling).

Secondary deficiency:

Infants, Children, and Adolescents:

Oral: Initial: 50 to 100 mg/kg/day in divided doses; reported frequency varies from 2 to 4 times daily up to every 3 to 4 hours; may titrate slowly as needed based on patient response; usual dose: 100 to 200 mg/kg/day; some patients may require higher doses (eg, 300 mg/kg/day); maximum daily dose: 3,000 mg/day (BIMDG 2016b; BIMDG 2020; Boy 2017; Shchelochkov 2020; Sutton 2012; manufacturer's labeling).

IV: 50 to 100 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, administer a loading dose based on patient's usual therapy, followed by an equivalent dose given over the next 24 hours as a continuous infusion or divided every 3 to 6 hours; some conditions may require higher daily doses (eg, 300 mg/kg/day) (BIMDG 2016b; BIMDG 2020; Boy 2017; Shchelochkov 2020; Sutton 2012; manufacturer's labeling).

Carnitine deficiency in patients with end-stage renal disease requiring dialysis

Carnitine deficiency in patients with end-stage renal disease (ESRD) requiring dialysis: Limited data available:

Note: Although described in manufacturer labeling, current guidelines do not support the use of levocarnitine in patients on dialysis (KDOQI 2009; KDIGO 2012).

Children and Adolescents: IV: 10 to 20 mg/kg dry body weight after each dialysis session; titrate dose based on serum concentrations; lower doses may be sufficient (manufacturer's labeling).

Cyclic vomiting syndrome, supplemental/adjunctive therapy

Cyclic vomiting syndrome, supplemental/adjunctive therapy: Limited data available:

Children and Adolescents: Oral: Initial: 50 to 100 mg/kg/day in divided doses 2 or 3 times daily; usual maximum dose: 1,000 mg/dose twice daily; higher doses (eg, up to a daily dose of 4,000 mg/day) have been used if needed based on laboratory testing of blood carnitine levels; however, this should be done with caution and careful monitoring of adverse events (eg, diarrhea) (Boles 2011; Kovacic 2018; Li 2018; Maqbool 2020; NASPGHAN [Li 2008]; Raucci 2020).

Valproic acid toxicity, acute

Valproic acid toxicity, acute: Limited data available:

Children and Adolescents: Dosing based on level of hepatic involvement and should be adjusted based on clinical response or serum level of valproic acid:

No hepatotoxicity: IV: 100 mg/kg/day divided every 6 hours until serum ammonia and valproic acid concentrations begin to decrease and clinical improvement is evident; maximum daily dose: 3,000 mg/day (Russell 2007).

Symptomatic hyperammonemia or hepatotoxicity: Reported dosing regimens variable: IV: Loading dose: 100 mg/kg; maximum loading dose: 6 g; followed by 15 mg/kg/dose every 4 to 6 hours; continue treatment until serum ammonia concentrations begin to decrease and clinical improvement is evident; patients may require several days of therapy. Doses of 50 mg/kg/dose (up to 3,000 mg/dose) every 8 hours have also been described (EASL 2019; Howland 2019; Perrott 2010; Russell 2007).

Dosing: Kidney Impairment: Pediatric

Oral: There are no dosage adjustments provided in the manufacturer's labeling; safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or with end-stage renal disease on dialysis may result in accumulation of potentially toxic metabolites.

IV: There are no dosage adjustments provided in the manufacturer's labeling; dosage adjustments should be determined based on levocarnitine levels and clinical response.

Dosing: Hepatic Impairment: Pediatric

Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Carnitine supplements (Levocarnitine): Drug information")

Carnitine deficiency

Carnitine deficiency:

Primary or secondary: Oral:

Oral solution: Initial: 1,000 mg/day in divided doses (every 3 to 4 hours throughout the day); titrate slowly as needed to 1,000 to 3,000 mg/day in divided doses based on tolerance and therapeutic response; higher doses may be needed in some patients (administer only with caution).

Tablet: 990 mg 2 to 3 times a day, depending on clinical response.

Secondary: IV: 50 mg/kg/day in divided doses (every 3 to 6 hours); subsequent doses in the range of 50 mg/kg/day or higher if clinically indicated (maximum reported dose: 300 mg/kg/day). In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an additional 50 mg/kg in divided doses over the next 24 hours may be required.

Carnitine deficiency in patients with ESRD requiring dialysis

Carnitine deficiency in patients with ESRD requiring dialysis: IV: 10 to 20 mg/kg (dry body weight) after each dialysis session; guide dosage adjustments by trough (predialysis) levocarnitine concentrations. Evaluate clinical response at 3-month intervals and titrate to the lowest effective dose; therapy should be discontinued if no improvement is seen after 9 to 12 months of therapy (Eknoyan 2003). Note: Current guidelines do not support the routine use of levocarnitine in dialysis patients (K/DOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).

Dietary supplement

Dietary supplement (OTC use): Oral: Refer to individual product labeling.

Valproic acid toxicity, acute

Valproic acid toxicity, acute (off-label use): IV: Initial: 100 mg/kg as an IV bolus followed by 50 mg/kg (maximum: 3,000 mg) as an IV bolus or intermittent infusion (over 15 to 30 minutes) every 8 hours; continue until ammonia levels are decreasing and clinical improvement is evident; patients may require several days of therapy (Perrott 2010). Some experts recommend a higher maximum loading dose (eg, 100 mg/kg [maximum: 6,000 mg]) and smaller, more frequent maintenance doses (eg, 15 mg/kg every 4 to 6 hours) in symptomatic patients (EASL 2019; Howland 2019; Russell 2007).

Dosing: Kidney Impairment: Adult

Oral: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites.

IV: There are no dosage adjustments provided in the manufacturer’s labeling; dosage adjustments should be determined by levocarnitine levels and clinical response. Note: Current guidelines do not support the routine use of levocarnitine in dialysis patients (K/DOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).

Dosing: Hepatic Impairment: Adult

Oral, IV: There are no dosage adjustments provided in the manufacturer’s labeling.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions include intravenous use in hemodialysis patients.

Frequency not defined:

Cardiovascular: Atrial fibrillation, chest pain, ECG abnormality, hypertension, palpitations, peripheral edema, tachycardia, vascular disease

Dermatologic: Body odor, skin rash, urticaria

Endocrine & metabolic: Hypercalcemia, parathyroid disorder, weight gain, weight loss

Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, diarrhea, dysgeusia, gastritis, melena, nausea, vomiting

Hematologic & oncologic: Anemia, hemorrhage

Hypersensitivity: Facial edema, hypersensitivity reaction (including anaphylaxis, bronchospasm, and laryngeal edema)

Infection: Infection

Nervous system: Asthenia, depression, dizziness, headache, myasthenia (uremic patients), paresthesia, seizure, vertigo

Ophthalmic: Amblyopia, eye disease

Renal: Renal failure syndrome

Respiratory: Bronchitis, cough, rhinitis

Miscellaneous: Fever

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Hypersensitivity to levocarnitine or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Gastrointestinal effects: GI reactions may result from too rapid consumption of oral carnitine; consume oral solution slowly and space doses evenly throughout the day to maximize tolerance.

• Hypersensitivity reactions: Serious hypersensitivity reactions have been reported after oral (eg, rash, urticaria, facial edema) and intravenous (eg, anaphylaxis, laryngeal edema, and bronchospasm) administration. Reactions from IV use have typically occurred in patients with end stage renal disease on dialysis and may occur within minutes after use. Discontinue immediately and institute appropriate medical therapy if an acute reaction occurs; consider risks and benefits of reinitiating therapy, and monitor patient for recurrence of severe hypersensitivity reaction if therapy is reinstated.

Disease-related concerns:

• Carnitine deficiency: Risk factors include: Age (infants and young children are deficient in the enzyme that activates carnitine), chronic valproic acid administration, concomitant neurologic disorders, congenital metabolic disorders, hepatic cirrhosis, renal failure, critical care patients (burns, sepsis, trauma, organ failure), use of multiple antiseizure drugs and other drugs (chemotherapy agents, antinucleoside analogues) (Katiyar 2007).

• Renal impairment: Safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites.

• Seizure disorder: Use with caution in patients with seizure disorders or in those at risk of seizures; both new-onset seizure activity as well as an increased frequency and/or severity of seizures has been observed.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Carnitor: 200 mg/mL (5 mL)

Generic: 200 mg/mL (5 mL)

Solution, Intravenous [preservative free]:

Generic: 200 mg/mL (20 mL)

Solution, Oral:

Carnitor: 1 g/10 mL (118 mL) [contains methylparaben, propylparaben; cherry flavor]

Carnitor SF: 1 g/10 mL (118 mL) [sugar free; contains methylparaben, propylparaben, saccharin sodium; cherry flavor]

G-levOCARNitine S/F: 1 g/10 mL (474 mL) [sugar free; contains methylparaben, propylene glycol, propylparaben]

Generic: 1 g/10 mL (5 mL, 10 mL, 118 mL)

Tablet, Oral:

Carnitor: 330 mg

Generic: 330 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Acticarnitine SF Oral)

1 g/10 mL (per mL): $0.05

Solution (Carnitor Intravenous)

200 mg/mL (per mL): $9.11

Solution (Carnitor Oral)

1 g/10 mL (per mL): $0.42

Solution (Carnitor SF Oral)

1 g/10 mL (per mL): $0.50

Solution (levOCARNitine (Dietary) Oral)

1 g/10 mL (per mL): $0.03

Solution (levOCARNitine Intravenous)

200 mg/mL (per mL): $8.56

Solution (levOCARNitine Oral)

1 g/10 mL (per mL): $0.39

Tablets (Carnitor Oral)

330 mg (per each): $1.47

Tablets (levOCARNitine (Dietary) Oral)

330 mg (per each): $0.34

Tablets (levOCARNitine L-Tartrate Oral)

330 mg (per each): $0.20

Tablets (levOCARNitine Oral)

330 mg (per each): $1.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Carnitor: 200 mg/mL (5 mL)

Solution, Oral:

Carnitor: 10% (118 mL) [contains methylparaben, propylparaben]

Generic: 10% (118 mL)

Tablet, Oral:

Carnitor: 330 mg

Administration: Pediatric

Oral: Oral solution: Administer undiluted or diluted in either beverages or liquid food; consume slowly; doses should be spaced evenly throughout the day, preferably during or following meals to improve tolerance.

Parenteral:

Carnitine deficiency: May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes or further diluted and administered as intermittent IV infusion over 30 minutes or as continuous infusion (BIMDG 2016a).

End-stage renal disease on hemodialysis: May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes into the venous return line.

Valproic acid toxicity: May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes or further diluted and administered as IV infusion over 10 to 30 minutes (Howland 2019; Perrott 2010; Russell 2007).

Administration: Adult

Oral solution: Solution is for oral use only (not for parenteral use); may be consumed alone or dissolved in either a drink or liquid food, and should be consumed slowly. Space doses every 3 to 4 hours evenly throughout the day, preferably during or following meals, to maximize tolerance.

IV:

Carnitine deficiency: Administer as a bolus dose over 2 to 3 minutes or by infusion. Doses should be administered every 3 to 4 hours, but never less than every 6 hours (eg, 4 doses/day).

Hemodialysis patients: Administer as a bolus dose over 2 to 3 minutes into the venous return line after each dialysis session.

Storage/Stability

Oral: Store at 20°C to 25°C (68°F to 77°F). Protect oral solution from freezing and excessive heat.

IV: IV solution is stable for up to 24 hours when mixed in NS or LR in PVC bags and stored at 25°C (77°F).

Pharmacy supply of emergency antidotes: Guidelines suggest that at least 9 to 15 g of levocarnitine be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.

Use

Oral: Solution, tablets: Treatment of primary or secondary carnitine deficiency (FDA approved in infants, children, and adults); dietary supplement of carnitine (dietary supplement indicated for use in adults); has also been used as a supplemental therapy in cyclic vomiting syndrome. Note: Approved ages and uses for dietary supplements may vary; consult product-specific labeling for details.

Parenteral: Treatment of secondary carnitine deficiency and prevention and treatment of carnitine deficiency in patients undergoing dialysis for end-stage renal disease (ESRD) (FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of valproic acid toxicity. Note: Although described in manufacturer labeling, current guidelines do not support the use of levocarnitine in patients on dialysis (KDIGO 2012; KDOQI 2009).

Medication Safety Issues
Sound-alike/look-alike issues:

LevOCARNitine may be confused with levETIRAcetam, levocabastine

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Vitamin K Antagonists (eg, warfarin): LevOCARNitine may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Teratogenic effects were not observed in animal studies. Carnitine is a naturally occurring substance in mammalian metabolism.

Monitoring Parameters

Carnitine serum concentrations should be obtained at baseline and subsequently monitored weekly to monthly. Monitor for diarrhea.

Metabolic disorders (primary or secondary carnitine deficiency): Blood chemistry, vital signs, and plasma carnitine concentration.

Valproic acid toxicity: Serum valproic acid concentrations (every 4 to 6 hours until a downward trend is observed), electrolytes, blood gases, mental status, hepatic function, serum ammonia concentration, serum lactate, and platelets.

Reference Range

Normal plasma free carnitine level: Neonates PNA ≥1 week, Infants, Children, and Adolescents: ≥20 micromoles/L; target plasma free carnitine level during therapy: 35 to 60 micromoles/L; to evaluate for carnitine deficiency, determine the plasma acylcarnitine/free carnitine ratio (A/F ratio).

A/F ratio = [plasma total carnitine - free carnitine] divided by free carnitine

Normal plasma A/F ratio = 0.25; in carnitine deficiency A/F ratio >0.4

Mechanism of Action

Carnitine is a naturally occurring metabolic compound which functions as a carrier molecule for long-chain fatty acids within the mitochondria, facilitating energy production. Carnitine deficiency is associated with accumulation of excess acyl CoA esters and disruption of intermediary metabolism.

In patients with valproic acid toxicity, the administration of exogenous carnitine shifts the metabolism of valproic acid toward beta-oxidation and away from omega-oxidation and potentially hepatotoxic metabolite production (Baddour 2018; Eyer 2005).

Pharmacokinetics (Adult Data Unless Noted)

Protein binding: None

Metabolism: Hepatic; Major metabolites: Trimethylamine (TMA) and trimethylamine N-oxide (TMAO)

Bioavailability: Oral solution: 15.9% ± 4.9%; Tablet: 15.1% ± 5.3%

Half-life elimination: 17.4 hours

Time to peak: Oral: 3.3 hours

Excretion: Urine (76%, 4% to 8% as unchanged drug); feces (<1%)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: L carnitine | L Carnitine | L-carnitine;
  • (AR) Argentina: Albicar | Carnitina | L Carnitina | L carnitina | Tonekin plus;
  • (AT) Austria: Biocarn | L-carnitin | Nefrocarnit;
  • (AU) Australia: L-carnithine | L-carnitine | Thermo blast;
  • (BD) Bangladesh: Carnitab | Carniten | Cartine | Envitor | Lenit | Levocar | Ocarnix;
  • (BG) Bulgaria: L carnitine | L-carnitine;
  • (BR) Brazil: L carnitina | Maxx carnitine;
  • (CH) Switzerland: Carnitene;
  • (CN) China: Carnitine | Lei ka;
  • (CO) Colombia: Carnisin | Carnitene | Carnitinova | Carnitor | Lecarnin;
  • (CZ) Czech Republic: Carnitene | L carnitin;
  • (DE) Germany: Allgamed | Biocarn | Cadion L Carnitin | Carnitin | Carnityl | Carnivita | CC Vital L Carnitin | Drofa l-carnitin | Echt vital L carnitin | Greenleaves vitamins acetyl l carnitin | L carnitin | L Carnitin | L carnitin 500 | L carnitine | L Carnitine | L-carnitin | Makomed L Carnitin | Manako L-Carnitin | Megamax L Carnitin | Nefrocarnit | Olebauer L Carnitine Fat Metabolism Support | Omnivit l Carnitin | Orthoextra carnitin | PhysiCal L-Carnitin;
  • (DO) Dominican Republic: Cardispan | Carnisin | Provicar;
  • (EC) Ecuador: Carnisin;
  • (EE) Estonia: Carnitene | Mr.max l-carnitine | Now L carnitine | Weight loss;
  • (EG) Egypt: Amricarnitine | Carnitene | Carnitine | Carnitol | Carnivita | Hydro bern | L-carnitine | L-carnttne | Levocarnine | Sunnycarnitine;
  • (ES) Spain: Carnicor | Secabiol;
  • (FR) France: Levocarnil;
  • (GB) United Kingdom: Carnitor | Levocarnitine | Levocarnitine paediatric;
  • (GR) Greece: Frutenor | Inestom | Levalastine | Levosan | Superamin | Trian | Trinalin;
  • (HK) Hong Kong: Carnitene | Carnitor;
  • (IE) Ireland: Carnitor;
  • (IL) Israel: L-carnitine;
  • (IN) India: Carnicare | Carnidin | Carniglo | Carnikid | Carnimed | Carnisure | Carnitor | Carnix | L-carpro | Lacarnit | Lencar | Levocarnil | Myocarnit | Nucarnit | Recarnit | Ree;
  • (IT) Italy: Branitil | Carnitene | Carnitina | Dromos | L-Carnitina | L-carnitina fonten | Lefcar;
  • (JO) Jordan: L carnitine | L Carnitine | L-Carnitine | L-carnitine | Lynae l-carnitine;
  • (JP) Japan: L Cartin | Levocarnitine chloride | Levocarnitine ff | Rhythm;
  • (KR) Korea, Republic of: Antifat | Carditone | Carnil | Cartin | Cartine l | D catin | Elcadol | Elgatin | Kaniel | Kareuel | L canin | L carina | L carnin | L carthin | L cartil | L catil | L liss | L queen | L tine | L top | L-carn | Lcaline | Lcanil | Lcarina | Lq | Myelcatin | Neucarotine | Slican;
  • (KW) Kuwait: L Carnitine;
  • (LB) Lebanon: L Carnitine | L carnitine | L karnitin | L-carnitine | Supravit l carnitine;
  • (LT) Lithuania: Carnitor | L carnitin | L carnitine | L-carnitine | L-Carnitine | Nefrocarnit;
  • (LV) Latvia: Acetil l carnitine | Bio-carnitin | L Carnitine | L-Carnitine | Mr.max l-carnitina;
  • (MX) Mexico: Cardispan | L-carnitina | Mince | Novacart | Provicar;
  • (MY) Malaysia: Carnitor | Gnc l carnitine | L Carnitine | L carnitine;
  • (NL) Netherlands: Carnitene | Levocarnitine eureco pharma | Levocarnitine Fisher | Nefrocarnit;
  • (NO) Norway: Carnicor | Carnitor | L-carnitin gph | Max carnitine;
  • (NZ) New Zealand: L-carnitine | Solgar l carnitine;
  • (PE) Peru: Cardispan;
  • (PH) Philippines: Cardimax | Carnicor | Legarde;
  • (PL) Poland: Carnitor;
  • (PR) Puerto Rico: Carnitine | Carnitor | Carnitor SF | L carnitine | L-carnitine | Levocarnitine;
  • (RU) Russian Federation: Carnitine | Elcar | Nephrocarnitis;
  • (SA) Saudi Arabia: Natrol l carnitine | Spermotil;
  • (SG) Singapore: L carnitine | L-carnitine;
  • (SI) Slovenia: Nefrocarnit;
  • (SK) Slovakia: Carnitene;
  • (TH) Thailand: Bio carnitine | L-carnitine | Vistra L Carnitine;
  • (TN) Tunisia: Levocarnil;
  • (TR) Turkey: Carnitene | L-carnitine | Nefro Carnitin | Nutraxin L Carnitine;
  • (TW) Taiwan: Carenephrin | Carnitene | Levocarnitin | Levolysis | Sinitine;
  • (UA) Ukraine: Agvantar | Almiba | Cardonat l-carnitine | Carnivit | Steatel;
  • (UY) Uruguay: Carnitil | Carnitina | Elecar | L-carnitine;
  • (VE) Venezuela, Bolivarian Republic of: Carnisin | Carnitene | Kativil | L carnitina | L-carnitina | Lecarnin | Lecart | Levocar | Lixi | Provicar | Rocarnin;
  • (VN) Viet Nam: Anbaluti;
  • (ZA) South Africa: Carnitine | Essentials l carnitine | Gold l carnitine | L carnitine | L Carnitine | L-carnitine;
  • (ZM) Zambia: Carnisure
  1. Almannai M, Alfadhel M, El-Hattab AW. Carnitine inborn errors of metabolism. Molecules. 2019;24(18):3251. doi:10.3390/molecules24183251 [PubMed 31500110]
  2. Baddour E, Tewksbury A, Stauner N. Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management. Ment Health Clin. 2018;8(2):73-77. doi:10.9740/mhc.2018.03.073 [PubMed 29955549]
  3. Boles RG. High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series. BMC Neurol. 2011;11:102. doi:10.1186/1471-2377-11-102 [PubMed 21846334]
  4. Boy N, Mühlhausen C, Maier EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017;40(1):75-101. doi:10.1007/s10545-016-9999-9 [PubMed 27853989]
  5. British Inherited Metabolic Disease Group (BIMDG). Carnitine transporter deficiency (CTD) - acute decompensation. https://www.bimdg.org.uk/store/guidelines/ER-CTD-v4_376453_09092016.pdf. Updated September 2016a. Accessed July 31, 2023.
  6. British Inherited Metabolic Disease Group (BIMDG). Glutaric aciduria type 1 - acute decompensation. https://www.bimdg.org.uk/store/guidelines/ER-GA1-v4_549337_05042017.pdf. Updated September 2016b. Accessed July 31, 2023.
  7. British Inherited Metabolic Disease Group (BIMDG). National formulary for inherited metabolic diseases (IMDs) 2nd edition. https://www.bimdg.org.uk/store/docs/BIMDG_Metabolic_Formulary_Second_Edition_October2020FINAL_582433_25102020.pdf. Published October 2020. Accessed July 31, 2023.
  8. Burton BK. Inherited metabolic disorders. In: Boardman J, Groves A, Ramasethu J, eds. Avery & MacDonald's Neonatology. 8th ed. LWW; 2021:chap. 55.
  9. Carnitor Oral Solution and Tablets (levocarnitine) [prescribing information]. Gaithersburg, MD: Leadiant Biosciences; June 2023.
  10. Carnitor Injection (levocarnitine) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; April 2018.
  11. Carnitor SF (levocarnitine) [prescribing information]. Gaithersburg, MD: Leadiant Biosciences; February 2020.
  12. Carnitor (levocarnitine) [product monograph]. Scarborough, Ontario, Canada: Leadiant Biosciences Inc; April 2019.
  13. Corkins MR, Balint J, Bobo E, et al, eds. The A.S.P.E.N Pediatric Nutrition Support Core Curriculum. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition; 2015.
  14. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  15. Eknoyan G, Latos DL, and Lindberg J, “Practice Recommendations for the Use of L-Carnitine in Dialysis-Related Carnitine Disorder. National Kidney Foundation Carnitine Consensus Conference,” Am J Kidney Dis, 2003, 41(4):868-76 [PubMed 12666074]
  16. European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014 [PubMed 30926241]
  17. Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol. 2005;25(4):376-380. doi:10.1097/01.jcp.0000168485.76397.5c [PubMed 16012283]
  18. Howland MA. Antidotes in depth: L-carnitine. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank's Toxicologic Emergencies. 11th ed. McGraw-Hill; 2019.
  19. Katiyar A and Aaron C, "Case Files of the Children's Hospital of Michigan Regional Poison Control Center: The Use of Carnitine for the Management of Acute Valproic Acid Toxicity," J Med Toxicol, 2007, 3(3):129-38. [PubMed 18072149]
  20. KDOQI Work Group, "KDOQI Clinical Practice Guideline for Nutrition in Children With CKD: 2008 Update. Executive Summary," Am J Kidney Dis, 2009, 53(3 Suppl 2):S11-104. [PubMed 19231749]
  21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;3:1-150.
  22. Kidney Disease Improving Global Outcomes (KDIGO) Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Intern Suppl. 2012;2(4):288-335.
  23. Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: what is new in 2018? Curr Gastroenterol Rep. 2018;20(10):46. doi:10.1007/s11894-018-0654-5 [PubMed 30159612]
  24. L-Carnitine [prescribing information]. Bohemia, NY: Nature's Bounty; received May 1, 2023.
  25. L-Carnitine [prescribing information]. Livonia, MI: Rugby Laboratories; July 2015.
  26. Levocarnitine [prescribing information]. Shirley, NY: American Regent Inc; January 2022.
  27. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol. 2009;47(2):101-111. [PubMed 19280426]
  28. Li BU, Lefevre F, Chelimsky GG, et al, "North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome," J Pediatr Gastroenterol Nutr, 2008, 47(3):379-93. [PubMed 18728540]
  29. Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. Eur J Pediatr. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7 [PubMed 30076469]
  30. Longo N. Primary carnitine deficiency and newborn screening for disorders of the carnitine cycle. Ann Nutr Metab. 2016;68(suppl 3):5-9. doi:10.1159/000448321 [PubMed 27931018]
  31. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C(2):77-85. [PubMed 16602102]
  32. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2012;7:68. [PubMed 22989098]
  33. Maqbool A, Li BUK, Liacouras CA. Cyclic vomiting syndrome. In: Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020: chap. 369.
  34. Mock CM and Schwetschenau KH, "Levocarnitine for Valproic Acid-Induced Hyperammonemic Encephalopathy," Am J Health Syst Pharm, 2012, 69(1):35-9. [PubMed 22180549]
  35. National Kidney Foundation, "KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease," Am J Kidney Dis, 2006, 47(5 Suppl 3):S11-145. [PubMed 16678659]
  36. National Kidney Foundation, “Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. K/DOQI,” Am J Kidney Dis, 2000, 35(6 Suppl 2):1-140. [PubMed 10895784]
  37. Perrott J, Murphy NG, and Zed PJ, "L-Carnitine for Acute Valproic Acid Overdose: A Systematic Review of Published Cases," Ann Pharmacother, 2010, 44(7-8):1287-93. [PubMed 20587742]
  38. Rasania M, Ahmed NM, Prafulchandra BV, Jain S. Primary carnitine deficiency in a neonate. Arch Med Health Sci. 2021;9:314-316
  39. Raucci U, Borrelli O, Di Nardo G, et al. Cyclic vomiting syndrome in children. Front Neurol. 2020;11:583425. doi:10.3389/fneur.2020.583425 [PubMed 33224097]
  40. Russell S, "Carnitine as an Antidote for Acute Valproate Toxicity in Children," Curr Opin Pediatr, 2007, 19(2):206-10. [PubMed 17496767]
  41. Shchelochkov OA, Manoli I, Venditti CP. Isoleucine, leucine, valine, and related organic acidemias. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020:chap. 103.6.
  42. Stanley CA, Bennett MJ. Defects in metabolism of lipids. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020:chap. 104.
  43. Sutton VR, Chapman KA, Gropman AL, et al. Chronic management and health supervision of individuals with propionic acidemia. Mol Genet Metab. 2012;105(1):26-33. [PubMed 21963082]
  44. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-491. doi:10.1177/0884533612446706 [PubMed 22730042]
  45. Wojcik MH. Inborn errors of metabolism. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. Cloherty and Stark's Manual of Neonatal Care. 9th ed. Lippincott Williams& Wilkins; 2022:chap. 60.
Topic 13119 Version 255.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟